evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

27 questions · 29 findings · 4 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 20.7%GRADE not reported 4 · 13.8%Very low 9 · 31%Low 6 · 20.7%Moderate 4 · 13.8%High 0 · 0%

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    over 3 months
    SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
    2 studies
    GRADE not reported

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    SoF 3 (NSAIDs vs placebo), Cancer development: SoF cell 'Not measured'. Effects text: cancer development was among outcomes in Papadimitrakopoulou 2008 (celecoxib) but did not occur in either arm, probably because of…
    1 study
    GRADE not reported

Ibuprofen vs ketorolac

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · children with acute postoperative pain

The review found no eligible studies for this question.

2 findings from 1 review

Ibuprofen vs ketorolac

Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain

The review found no eligible studies for this question.

1 finding from 1 review